<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2532">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04389437</url>
  </required_header>
  <id_info>
    <org_study_id>AMR_2020_3</org_study_id>
    <nct_id>NCT04389437</nct_id>
  </id_info>
  <brief_title>OCT-Angiography and Adaptive Optics in Patients With Memory Impairment</brief_title>
  <acronym>OCTAVO</acronym>
  <official_title>OCT-Angiography and Adaptive Optics in Patients With Memory Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondation Ophtalmologique Adolphe de Rothschild</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondation Ophtalmologique Adolphe de Rothschild</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Studies suggest an association between retinal abnormalities and NCD (Neuro Cognitive&#xD;
      Disorders) whether they are linked to proven or prodromal Alzheimer's disease (aMCI :&#xD;
      amnestic mild cognitive impairment), or to other neurodegenerative diseases such as&#xD;
      frontotemporal dementia or Lewy body diseases.&#xD;
&#xD;
      These retinal anomalies objectified by OCT-A (Optical coherence tomography angiography) and&#xD;
      adaptive optics (AO) appear different depending on the pathologies and could therefore serve&#xD;
      as markers in vivo of the pathophysiological processes underlying NCD.&#xD;
&#xD;
      No study to date has studied the retina and its vessels in NCD using adaptive optics. In this&#xD;
      pilot study, we are proposing a combination of two new ophthalmological imaging techniques&#xD;
      (OCT-A and AO), which allow rapid in vivo analysis in a completely non-invasive way of the&#xD;
      morphology of small vessels as well as architecture of the retina to better specify the&#xD;
      retinal anomalies associated with NCD. We will compare the parameters in OCT-A and AO between&#xD;
      patients with NCD and controls without NCD (with memory complaint or without) and will seek&#xD;
      to determine if there are different profiles according to the causes of NCD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 26, 2020</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Wall to lumen ratio (WLR)</measure>
    <time_frame>Baseline (Inclusion)</time_frame>
    <description>Measured in adaptive optics, compared between patients case with NCD and patient controls without NDC found</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Amnesia</condition>
  <condition>Alzheimer Disease</condition>
  <condition>Lewy Body Disease</condition>
  <condition>Parkinsons Disease With Dementia</condition>
  <arm_group>
    <arm_group_label>NCD patients (case)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient diagnosed with Alzheimer's disease or parkinsonian dementia / Lewy body dementia or other mild or severe NCD defined by international criteria.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control patients with memory complaint</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Normal neuropsychological evaluation during assessment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control patients without memory complaint</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>MMS score and / or the Montreal Cognitive Assessment grid (MoCA) ≥26 / 30, No memory complaint</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ophthalmological exam</intervention_name>
    <description>OCT-A and AO</description>
    <arm_group_label>Control patients with memory complaint</arm_group_label>
    <arm_group_label>Control patients without memory complaint</arm_group_label>
    <arm_group_label>NCD patients (case)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood pressure measurement</intervention_name>
    <description>Blood pressure measurement before the ophthalmological exam</description>
    <arm_group_label>Control patients with memory complaint</arm_group_label>
    <arm_group_label>Control patients without memory complaint</arm_group_label>
    <arm_group_label>NCD patients (case)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient presenting in memory consultation for memory complaint or person accompanying&#xD;
             a patient in memory consultation for memory complaint&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnant or lactating women&#xD;
&#xD;
          -  history of known non-degenerative neurological pathology (tumor, stroke territorial,&#xD;
             in particular multiple sclerosis)&#xD;
&#xD;
          -  history of retinal pathology&#xD;
&#xD;
          -  ametropia greater in absolute value than 3 diopters on the sphere, and 1.5 diopters on&#xD;
             the cylinder.&#xD;
&#xD;
          -  history of taking ethambutol or synthetic antimalarial&#xD;
&#xD;
          -  Mini Mental State Score (MMS) and / or Montreal Cognitive Assessment (MoCA) &lt;10 for&#xD;
             patients and 26 for accompanying persons&#xD;
&#xD;
          -  MRI contraindication (for patients only)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antoine MOULIGNIER, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondation A. de Rothschild</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amélie YACHITZ, MD</last_name>
    <phone>(0)148036454</phone>
    <phone_ext>+33</phone_ext>
    <email>ayavchitz@for.paris</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Antoine MOULIGNIER, MD</last_name>
    <email>amoulignier@for.paris</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Fondation A. de Rothschild</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine MOULIGNIER, MP</last_name>
      <email>amoulignier@for.paris</email>
    </contact>
    <contact_backup>
      <last_name>Martine MAUGET FAYSSE, MD</last_name>
      <phone>(0)148036437</phone>
      <phone_ext>+33</phone_ext>
      <email>mmfaysse@for.paris</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2022</verification_date>
  <study_first_submitted>May 12, 2020</study_first_submitted>
  <study_first_submitted_qc>May 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2020</study_first_posted>
  <last_update_submitted>July 22, 2022</last_update_submitted>
  <last_update_submitted_qc>July 22, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">July 25, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>OCT-A</keyword>
  <keyword>adaptative optics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Lewy Body Disease</mesh_term>
    <mesh_term>Amnesia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

